Volvo announces updated share and vote count after series conversion

Martin Lundstedt President and CEO at Volvo Group North America LLC Volvo Group North America LLC
Martin Lundstedt President and CEO at Volvo Group North America LLC - Volvo Group North America LLC
0Comments

The number of votes in AB Volvo has changed following the conversion of 2,000,619 Series A shares into an equal number of Series B shares. This option for shareholders to convert Series A shares to Series B shares was established in the Articles of Association at the company’s 2011 Annual General Meeting.

As of February 27, 2026, which is the last trading day of the month, AB Volvo has a total of 2,033,452,084 registered shares. Of these, there are 442,288,469 Series A shares and 1,591,163,615 Series B shares. The total number of votes in the company now stands at 601,404,830.50 based on these figures.

“This information is information that AB Volvo (publ) is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication at 13.15 p.m. CET on 27 February, 2026.”

For further details about this change or other corporate matters at AB Volvo, journalists can contact Claes Eliasson, Head of Media Relations.

AB Volvo was founded in Gothenburg in 1927 and currently employs nearly 100,000 people worldwide. The company provides transport and infrastructure solutions including trucks and buses as well as equipment for construction and power applications. In addition to its global reach across almost 180 markets, Volvo reported net sales totaling SEK 479 billion (EUR 43 billion) in 2025. Its stock is listed on Nasdaq Stockholm.

More details about the company can be found at volvogroup.com.



Related

Paul Hudson Chief Executive Officer Sanofi SA

Acoziborole receives key EU panel backing as single-dose treatment for sleeping sickness

Acoziborole Winthrop, a new oral treatment for sleeping sickness developed by the Drugs for Neglected Diseases initiative (DNDi) and Sanofi, has received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for…

Paul Hudson Chief Executive Officer Sanofi SA

Sanofi and Regeneron’s Dupixent recommended for EU approval in young children with chronic urticaria

Sanofi and Regeneron have announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending approval of Dupixent (dupilumab) for children aged two to 11 years with…

Dr. h. c. mult. Pekka Ala-Pietilae Chairman of the Supervisory Board SAP SE SAP SE

SAP files annual report for 2025 with SEC and releases integrated report

SAP SE has announced the filing of its Annual Report on Form 20-F for the year ending December 31, 2025, with the U.S. Securities and Exchange Commission (SEC).

Trending

The Weekly Newsletter

Sign-up for the Weekly Newsletter from EU Business Daily.